Loop33 × 123 CAR-T targeting CD33 and CD123 against immune escape in acute myeloid leukemia.

ABSTRACT:

Background

Immunotherapy, such as chimeric antigen receptor T (CAR-T) cells targeting CD33 or CD123, has been well developed over the past decade for the treatment of acute myeloid leukemia (AML). However, the inability to sustain tumor-free survival and the possibility of relapse due to antigen loss have raised concerns. A dual targeting of CD33 and CD123 is needed for better outcomes.

Methods

Based on our previously constructed CD33 and CD123 monovalent CAR-T, Loop33 × 123 and Loop123 × 33 CAR-T were constructed with molecular cloning techniques. All CAR-T cells were generated by lentivirus transduction of T cells from healthy donors. Phenotype detection was evaluated on day 7 concerning activation, exhaustion, and subtype proportions. Coculture killing assays were conduct

SUBMITTER: Ma H 

PROVIDER: S-EPMC11561222 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature